Exercise4

BIO-RAD LABORATORIES, INC.

Total Value

$329.7K

Filing Date

Sep 9, 2026

1 transactions

Trade Summary

On Sep 4, 2026 through Sep 6, 2026, ENGELHARDT EVA ANETTE, EVP, President, CDG, reported $329.7K of BIO-RAD LABORATORIES, INC. (BIO BIO.B) across 1 transactions. The filing covers Bio-Rad A Common Stock and reflects balanced net activity of $0. Reported prices ranged from $386.11. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: ENGELHARDT EVA ANETTE
Role: EVP, President, CDG
Location: HERCULES, CA

Filing Details

Filing Date: Sep 9, 2026
Transaction Date: Sep 4, 2026
Accession Number: 0002024911-26-000006
Form Type: 4

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Sep 5, 2026	Bio-Rad A Common Stock	1,027	—	Exercise	—
Sep 5, 2026	Bio-Rad A Common Stock	369	$386.11	Tax Withholding	$142.5K
Sep 6, 2026	Bio-Rad A Common Stock	1,152	—	Exercise	—
Sep 6, 2026	Bio-Rad A Common Stock	485	$386.11	Tax Withholding	$187.3K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Sep 4, 2026	BIO BIO.B derivative	4,313	—	Grant/Award	—
Sep 5, 2026	BIO BIO.B derivative	1,027	—	Exercise	—
Sep 6, 2026	BIO BIO.B derivative	1,152	—	Exercise	—

Want live alerts when ENGELHARDT EVA ANETTE trades again?

Download Insider Trades to track BIO BIO.B, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)Shares of Class A common stock acquired on the vesting of restricted stock units.
(F2)Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
(F3)The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
(F4)The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ENGELHARDT EVA ANETTE

(Last)

(First)

(Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES

94547

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, President, CDG

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Bio-Rad A Common Stock	09/05/2026		M		1,027⁽¹⁾	A	$0	1,530	D
Bio-Rad A Common Stock	09/05/2026		F		369	D	$386.11	1,161	D
Bio-Rad A Common Stock	09/06/2026		M		1,152⁽¹⁾	A	$0	2,313	D
Bio-Rad A Common Stock	09/06/2026		F		485	D	$386.11	1,828	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0⁽²⁾	09/04/2026		A		4,313		⁽³⁾	⁽³⁾	Bio-Rad A Common Stock	4,313	$0	4,313	D
Restricted Stock Units	$0⁽²⁾	09/05/2026		M			1,027	⁽⁴⁾	⁽⁴⁾	Bio-Rad A Common Stock	1,027	$0	3,083	D
Restricted Stock Units	$0⁽²⁾	09/06/2026		M			1,152	⁽⁴⁾	⁽⁴⁾	Bio-Rad A Common Stock	1,152	$0	2,304	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.

4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Eva Anette Engelhardt	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0002024911-26-000006.

BIO-RAD LABORATORIES, INC.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when ENGELHARDT EVA ANETTE trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4